OverviewChartNewsTraderScreen

Soc. Generale Discount Zert ATO 2.../  DE000SU1TZR2  /

Frankfurt Zert./SG
2024-06-04  4:41:02 PM Chg.-0.140 Bid5:30:16 PM Ask- Underlying Strike price Expiration date Option type
1.170EUR -10.69% -
Bid Size: -		 -
Ask Size: -		 Atos SE - EUR 2024-06-28 Call
GlobeNewswire 05-30 Groundbreaking Technology Solves Major Problem of User Lockouts During MFA Resets
GlobeNewswire 05-28 NetLogistik Wins Partner Leadership Award from Blue Yonder
GlobeNewswire 05-28 Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast...
GlobeNewswire 05-16 Nametag Enlisted by Newfold Digital in the Fight Against Fraud and Cybersecurity Threats
GlobeNewswire 05-15 Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Tria...
GlobeNewswire 05-15 Calian Reports Record Results for the Second Quarter
GlobeNewswire 05-13 Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 05-13 NVIDIA Grace Hopper Ignites New Era of AI Supercomputing
GlobeNewswire 05-07 Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
GlobeNewswire 04-29 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...
GlobeNewswire 04-15 Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endo...
GlobeNewswire 04-11 Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
GlobeNewswire 04-09 Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100%...
GlobeNewswire 04-01 Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
GlobeNewswire 03-27 Calian Announces the Appointment of New President of Advanced Technologies
GlobeNewswire 03-25 Nametag Launches Self-Service Account Recovery Solution That Stops AI-Generated Deepfake Attacks
GlobeNewswire 03-19 Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Acce...
GlobeNewswire 03-18 Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
GlobeNewswire 03-12 Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Dir...
GlobeNewswire 03-06 Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Can...
GlobeNewswire 02-22 Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
GlobeNewswire 01-16 New report reveals that 94% of global organizations have experienced email security incidents last y...
GlobeNewswire 01-09 Atossa Therapeutics Issues Letter to Shareholders
TeleTrader 01-03 Europe opens mixed with data, business in focus
TeleTrader 01-03 Airbus to purchase Atos' cyber security unit for $1.9B